Overview

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Phase:
PHASE1
Details
Lead Sponsor:
ALX Oncology Inc.